{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T20:13:22Z","timestamp":1792872802483,"version":"4.5.0"},"reference-count":29,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,3,6]],"date-time":"2023-03-06T00:00:00Z","timestamp":1678060800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["220530\/Z\/20\/Z"],"award-info":[{"award-number":["220530\/Z\/20\/Z"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bjoms.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["British Journal of Oral and Maxillofacial Surgery"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1016\/j.bjoms.2023.02.003","type":"journal-article","created":{"date-parts":[[2023,3,2]],"date-time":"2023-03-02T21:27:13Z","timestamp":1677792433000},"page":"227-232","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Case series of medication-related osteonecrosis of the jaw (MRONJ) patients prescribed a drug holiday"],"prefix":"10.1016","volume":"61","author":[{"given":"Aruche","family":"Hamid","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Bell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Gormley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bjoms.2023.02.003_b0005","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/S0278-2391(03)00720-1","article-title":"Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic","volume":"61","author":"Marx","year":"2003","journal-title":"J Oral Maxillofac Surg"},{"key":"10.1016\/j.bjoms.2023.02.003_b0010","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s10147-013-0561-6","article-title":"Risk of osteonecrosis of the jaw in cancer patients receiving denosumab: a meta-analysis of seven randomized controlled trials","volume":"19","author":"Qi","year":"2014","journal-title":"Int J Clin Oncol"},{"key":"10.1016\/j.bjoms.2023.02.003_b0015","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s10549-010-0866-3","article-title":"Bevacizumab and osteonecrosis of the jaw: incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer","volume":"122","author":"Guarneri","year":"2010","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.bjoms.2023.02.003_b0020","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/jbmr.2405","article-title":"Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus","volume":"30","author":"Khan","year":"2015","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.bjoms.2023.02.003_b0025","unstructured":"Scottish Dental Clinical Effectiveness Programme. Oral Health Management of Patients at Risk of Medication-related Osteonecrosis of the Jaw, 2017. Available from URL: https:\/\/www.sdcep.org.uk\/published-guidance\/medication-related-osteonecrosis-of-the-jaw\/ (last accessed 6 March 2023)."},{"key":"10.1016\/j.bjoms.2023.02.003_b0030","unstructured":"Royal College of Physicians. Medication-related osteonecrosis of the jaw: Guidance for the oncology multidisciplinary team 2019. Available from URL: https:\/\/www.rcplondon.ac.uk\/guidelines-policy\/medication-related-osteonecrosis-jaw-guidance-oncology-multidisciplinary-team (last accessed 6 March 2023)."},{"key":"10.1016\/j.bjoms.2023.02.003_b0035","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.ygyno.2008.11.029","article-title":"Bisphosphonate-induced osteonecrosis of the jaw (ONJ): incidence and risk factors in patients with breast cancer and gynecological malignancies","volume":"112","author":"Fehm","year":"2009","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.bjoms.2023.02.003_b0040","doi-asserted-by":"crossref","first-page":"5356","DOI":"10.1200\/JCO.2009.21.9584","article-title":"Longitudinal cohort study of risk factors in cancer patients of bisphosphonate-related osteonecrosis of the jaw","volume":"27","author":"Vahtsevanos","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bjoms.2023.02.003_b0045","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1093\/annonc\/mdr435","article-title":"Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases","volume":"23","author":"Saad","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1016\/j.bjoms.2023.02.003_b0050","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.joms.2014.07.012","article-title":"Temporal correlation between bisphosphonate termination and symptom resolution in osteonecrosis of the jaw: a pooled case report analysis","volume":"73","author":"Hinson","year":"2015","journal-title":"J Oral Maxillofac Surg"},{"key":"10.1016\/j.bjoms.2023.02.003_b0055","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1016\/j.joms.2022.02.008","article-title":"American Association of Oral and Maxillofacial Surgeons\u2019 position paper on medication-related osteonecrosis of the jaws \u2013 2022 update","volume":"80","author":"Ruggiero","year":"2022","journal-title":"J Oral Maxillofac Surg"},{"key":"10.1016\/j.bjoms.2023.02.003_b0060","first-page":"33","article-title":"Bisphosphonate-related osteonecrosis of the jaws: a potential alternative to drug holidays","volume":"61","author":"Damm","year":"2013","journal-title":"Gen Dent"},{"key":"10.1016\/j.bjoms.2023.02.003_b0065","doi-asserted-by":"crossref","first-page":"2270","DOI":"10.1200\/JCO.19.01186","article-title":"Medication-related osteonecrosis of the jaw: MASCC\/ISOO\/ASCO clinical practice guideline","volume":"37","author":"Yarom","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bjoms.2023.02.003_b0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2020.e03795","article-title":"Efficacy of a high-dose antiresorptive drug holiday to reduce the risk of medication-related osteonecrosis of the jaw (MRONJ): a systematic review","volume":"6","author":"Ottesen","year":"2020","journal-title":"Heliyon"},{"key":"10.1016\/j.bjoms.2023.02.003_b0075","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1186\/s12967-019-2129-3","article-title":"Identifying genetic variants underlying medication-induced osteonecrosis of the jaw in cancer and osteoporosis: a case control study","volume":"17","author":"Lee","year":"2019","journal-title":"J Transl Med"},{"key":"10.1016\/j.bjoms.2023.02.003_b0080","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1080\/10428194.2017.1300889","article-title":"Genetic factors related with early onset of osteonecrosis of the jaw in patients with multiple myeloma under zoledronic acid therapy","volume":"58","author":"Kastritis","year":"2017","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.bjoms.2023.02.003_b0085","doi-asserted-by":"crossref","first-page":"107","DOI":"10.2165\/00044011-200525020-00003","article-title":"Pharmacokinetic considerations in determining the terminal elimination half-lives of bisphosphonates","volume":"25","author":"Lasseter","year":"2005","journal-title":"Clin Drug Investig"},{"key":"10.1016\/j.bjoms.2023.02.003_b0090","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1002\/hed.21708","article-title":"Factors influencing surgical treatment of bisphosphonate-related osteonecrosis of the jaws","volume":"34","author":"Wutzl","year":"2012","journal-title":"Head Neck"},{"key":"10.1016\/j.bjoms.2023.02.003_b0095","doi-asserted-by":"crossref","first-page":"206","DOI":"10.5125\/jkaoms.2014.40.5.206","article-title":"Drug holiday as a prognostic factor of medication-related osteonecrosis of the jaw","volume":"40","author":"Kim","year":"2014","journal-title":"J Korean Assoc Oral Maxillofac Surg"},{"key":"10.1016\/j.bjoms.2023.02.003_b0100","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/j.ijom.2006.02.022","article-title":"Bisphosphonate-induced avascular osteonecrosis of the jaws: a clinical report of 11 cases","volume":"35","author":"Dimitrakopoulos","year":"2006","journal-title":"Int J Oral Maxillofac Surg"},{"key":"10.1016\/j.bjoms.2023.02.003_b0105","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1002\/jbmr.4119","article-title":"A drug holiday reduces the frequency and severity of medication-related osteonecrosis of the jaw in a minipig model","volume":"35","author":"Otto","year":"2020","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.bjoms.2023.02.003_b0110","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1007\/s00784-017-2325-6","article-title":"Stage-specific therapeutic strategies of medication-related osteonecrosis of the jaws: a systematic review and meta-analysis of the drug suspension protocol","volume":"22","author":"Ramaglia","year":"2018","journal-title":"Clin Oral Investig"},{"key":"10.1016\/j.bjoms.2023.02.003_b0115","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.tripleo.2010.04.015","article-title":"The role of surgical therapy in the management of intravenous bisphosphonates-related osteonecrosis of the jaw","volume":"111","author":"Wilde","year":"2011","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol Endod"},{"key":"10.1016\/j.bjoms.2023.02.003_b0120","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/j.jcms.2017.01.013","article-title":"Clinical course and therapeutic outcomes of operatively and non-operatively managed patients with denosumab-related osteonecrosis of the jaw (DRONJ)","volume":"45","author":"Hoefert","year":"2017","journal-title":"J Craniomaxillofac Surg"},{"key":"10.1016\/j.bjoms.2023.02.003_b0125","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1016\/j.jcms.2018.05.046","article-title":"Osteonecrosis of the jaw in patients treated with denosumab: a multicenter case series","volume":"46","author":"Aljohani","year":"2018","journal-title":"J Craniomaxillofac Surg"},{"key":"10.1016\/j.bjoms.2023.02.003_b0130","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1016\/j.ijom.2012.05.012","article-title":"The outcomes of conservative and surgical treatment of stage 2 bisphosphonate-related osteonecrosis of the jaws: a case series","volume":"41","author":"Jabbour","year":"2012","journal-title":"Int J Oral Maxillofac Surg"},{"key":"10.1016\/j.bjoms.2023.02.003_b0135","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1016\/j.joms.2015.01.008","article-title":"Surgical therapy for bisphosphonate-related osteonecrosis of the jaw: six-year experience of a single institution","volume":"73","author":"Lopes","year":"2015","journal-title":"J Oral Maxillofac Surg"},{"key":"10.1016\/j.bjoms.2023.02.003_b0140","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.oooo.2015.10.033","article-title":"Surgical management of bisphosphonate-related osteonecrosis of the jaw stages II and III","volume":"121","author":"Bodem","year":"2016","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol"},{"key":"10.1016\/j.bjoms.2023.02.003_b0145","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1111\/odi.12966","article-title":"Drug holiday patterns and bisphosphonate-related osteonecrosis of the jaw","volume":"25","author":"Jung","year":"2019","journal-title":"Oral Dis"}],"container-title":["British Journal of Oral and Maxillofacial Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0266435623000645?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0266435623000645?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T15:31:42Z","timestamp":1759419102000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0266435623000645"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":29,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["S0266435623000645"],"URL":"https:\/\/doi.org\/10.1016\/j.bjoms.2023.02.003","relation":{},"ISSN":["0266-4356"],"issn-type":[{"value":"0266-4356","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Case series of medication-related osteonecrosis of the jaw (MRONJ) patients prescribed a drug holiday","name":"articletitle","label":"Article Title"},{"value":"British Journal of Oral and Maxillofacial Surgery","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bjoms.2023.02.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Ltd on behalf of The British Association of Oral and Maxillofacial Surgeons.","name":"copyright","label":"Copyright"}]}}